Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HTM | Q9NXG6 | 16/20 | 0.60 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL795541 | 0.83 | MAPK1 (0.51) | P4HTMKDM4EMAPK1L3MBTL1 | |
| SCHEMBL26049197 | 0.80 | P4HTM (0.62) | P4HTMP4HA1MIFKDM4EALDH1A1 | |
| SCHEMBL13954312 | 0.79 | P4HTM (0.61) | P4HTMP4HA1MIFKDM4EALDH1A1 | |
| SCHEMBL27911280 | 0.78 | TYK2 (0.38) | P4HTMKDM4EL3MBTL1 | |
| SCHEMBL18405340 | 0.78 | P4HTM (0.60) | P4HTMP4HA1MIFKDM4EALDH1A1 | |
| SCHEMBL30112058 | 0.78 | P4HTM (0.60) | P4HTMP4HA1MIFKDM4EALDH1A1 | |
| SCHEMBL796214 | 0.77 | MAPK1 (0.44) | P4HTMKDM4EMAPK1L3MBTL1 | |
| SCHEMBL22050225 | 0.76 | P4HTM (0.58) | P4HTMP4HA1MIFKDM4EALDH1A1 | |
| SCHEMBL11396052 | 0.75 | P4HTM (1.00) | P4HTMKDM4EALDH1A1 | |
| SCHEMBL63831 | 0.74 | P4HTM (0.56) | P4HTMP4HA1MIFKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616465-B1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2015-11-04 | — | — | EP | disclosed |
| US-20150025057-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| US-8895733-B2 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-11-25 | — | — | US | disclosed |
| US-20140051676-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-02-20 | — | — | US | disclosed |
| EP-2616465-A1 | TRIAZINE-OXADIAZOLES | Novartis AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| CN-103221408-A | Triazine-oxadiazole compounds | NOVARTIS AG | 2013-07-24 | — | — | CN | disclosed |
| WO-2012035023-A1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025057-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | P4HTM 1564/4885P4HA1 1090/4885MIF 858/4885 |
| US-20140051676-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | P4HTM 1564/4885P4HA1 1090/4885MIF 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.